EU & NICE authorise MSD’s Keytruda for stage III melanoma
MSD’s Keytruda has been given a green light for use within the EU as an adjuvant treatment for stage III melanoma, and has also been made available on the NHS.
Read More
Author: Selina McKee
GSK and Pfizer to create consumer healthcare JV
GlaxoSmithKline and Pfizer have unveiled plans to combine their consumer health businesses into a new world-leading Joint Venture worth around £9.8 billion.
Read More
Nearly half of CCGs rated ‘requires improvement’ or ‘inadequate’
A new report from the National Audit Office has found that In 2017-18, 42% (87 of 207) of Clinical Commissioning Groups (CCGs) were rated either ‘requires improvement’ or ‘inadequate’, with as little as 10% rated as ‘outstanding’.
Read More
Verona initiates Phase II trial for COPD powder inhaler
Verona has announced the start of a Phase II clinical trial to evaluate a dry powder inhaler formulation of RPL554 in patients with moderate to severe chronic obstructive pulmonary disease.
Read More
All practices in England now offering extended GP access
NHS England has announced that patients across England can now access general practice (GP) appointments in the evening and weekends, resulting in as many as nine million extra appointments per year.
Read More- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
